<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Pretomanid" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Pretomanid</book-part-id>
      <title-group>
        <title>Pretomanid</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>11</month>
          <year>2019</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Pregabalin" document-type="chapter">Pregabalin</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Primaquine" document-type="chapter">Primaquine</related-object>
    </book-part-meta>
    <body>
      <sec id="Pretomanid.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Pretomanid.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Pretomanid is a nitroimidazooxazine antimycobacterial agent used in combination with other antituberculosis drugs in the treatment of multidrug resistant tuberculosis. The addition of pretomanid to antituberculosis drug regimens has been linked to an increased rate of transient serum liver test abnormalities during treatment and to several instances of mild, clinically apparent liver injury.</p>
        </sec>
        <sec id="Pretomanid.Background">
          <title>Background</title>
          <p>Pretomanid (pre toe&#x02019; ma nid) is a unique antimycobacterial agent that has activity against multidrug resistant mycobacterium tuberculosis both in vitro and in vivo and was first approved for use in the United States in 2019. A nitroimidazooxazine, pretomanid is believed to act via inhibition of mycolic acid synthesis, blocking mycobacterial cell wall synthesis. Its current indications are for multidrug resistant pulmonary tuberculosis in combination with other antituberculosis agents. It is not approved for use in latent or drug sensitive tuberculosis or in atypical mycobacterial infections. In addition, pretomanid has not been shown to be effective for extra-pulmonary tuberculosis. Pretomanid is available in tablets of 200 mg under the brand name Pretomanid. The recommended dose is 200 mg once daily in combination with bedaquiline and linezolid for 26 weeks. Side effects of this regimen are common and include peripheral neuropathy, acne, anemia, nausea, vomiting, dyspepsia, anorexia, weight loss, diarrhea, abdominal pain, headache, rash, pruritus, cough, pleuritic pain, hemoptysis, back pain, visual impairment and hypoglycemia. Laboratory abnormalities include anemia and increases in serum aminotransferase levels and amylase. Rare, but potentially serious adverse reactions include myelosuppression, peripheral and optic neuropathy, prolongation of the QTc interval, lactic acidosis and reproductive effects including impaired fertility.</p>
          <p>The management of multidrug resistant tuberculosis is challenging and should be under the direction of physicians with expertise in tuberculosis therapy and management of its side effects. Optimal regimens of therapy for tuberculosis are complex and change frequently. Regularly updated recommendations on use of pretomanid and other drugs for tuberculosis, including indications, contraindications, warnings, dosages and monitoring recommendations are available at the Centers for Disease Control and Prevention website: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/tb/publications/guidelines/Treatment.htm">http://www.cdc.gov/tb/publications/guidelines/Treatment.htm</ext-link>.</p>
        </sec>
        <sec id="Pretomanid.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Liver test abnormalities occur in 30% of patients treated with multiple drug regimens that include pretomanid. These abnormalities are usually asymptomatic, mild-to-moderate in severity and self-limited in duration. In many instances, it is difficult to determine which of the antituberculosis medications account for the abnormalities, but regular monitoring of liver tests is recommended during triple therapy with pretomanid, bedaquiline and linezolid. Clinically apparent liver injury has been reported with pretomanid-based therapies, but largely in regimens that included moxifloxacin or pyrazinamide or both. The clinical features, course and outcome of these cases has not been well defined. In the pivotal study of pretomanid combined with bedaquiline and linezolid in 109 adults with drug resistant pulmonary tuberculosis, 12 patients (11%) developed ALT levels above 3 times the upper limit of normal (ULN) of whom two also developed mild jaundice (bilirubin above twice but less than 3 times ULN) arising during month two of therapy. Both patients had mild nausea accompanying the liver test abnormalities, and the abnormalities resolved in both with temporary interruption in treatment, followed by re-initiation using lower dose linezolid without change in the pretomanid dose. In this pivotal trial, most adverse events were attributed to linezolid.</p>
          <p>Likelihood score: D (possible cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Pretomanid.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which pretomanid might cause serum aminotransferase elevations or clinically apparent liver injury is not known but is likely due to production of a toxic intermediate during its metabolism. Pretomanid is metabolized by the liver via multiple reductive and oxidative pathways, the P450 system (predominantly CPY 3A4) accounting for approximately 20% of its metabolism. Nevertheless, pretomanid is susceptible to drug-drug interactions with agents that induce or inhibit CYP3A4 and with substrates of the organic anion transporter 3 (OAT-3) which also participates it is metabolism and excretion.</p>
        </sec>
        <sec id="Pretomanid.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>Patients on pretomanid should be monitored with liver tests, including serum bilirubin, ALT, AST and alkaline phosphatase before starting therapy and at intervals thereafter. Pretomanid should be discontinued for persistent increases in liver test abnormalities, ALT elevations accompanied by increases in total bilirubin of more than twice normal or by any symptom or sign of liver injury. There is no evidence to suggest cross sensitivity to liver injury or adverse events between pretomanid and other antituberculosis medications.</p>
          <p>Drug Class: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/AntituberculosisAgen/"><underline>Antituberculosis Agents</underline></ext-link></p>
          <p>Other Drugs in the Class: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK548859/">Bedaquline</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK548641/">Capreomycin</ext-link>,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Cycloserine/"><underline>Cycloserine</underline></ext-link>,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Ethambutol/"><underline>Ethambutol</underline></ext-link>,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Ethionamide/"><underline>Ethionamide</underline></ext-link>,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Isoniazid/"><underline>Isoniazid</underline></ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Pyrazinamide/"><underline>Pyrazinamide</underline></ext-link>,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Rifabutin/"><underline>Rifabutin</underline></ext-link>,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Rifampin/"><underline>Rifampin</underline></ext-link>,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Rifapentine/"><underline>Rifapentine</underline></ext-link>,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://preview.ncbi.nlm.nih.gov/books/prevqa/n/livertox/Streptomycin/"><underline>Streptomycin</underline></ext-link></p>
        </sec>
      </sec>
      <sec id="Pretomanid.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Pretomanid &#x02013; Pretomanid&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antituberculosis Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af277d80-ac01-4aaf-87b8-86a152a7f323">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Pretomanid.CHEMICAL_FORMULA_AND_STRUCTUR">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Pretomanid.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Pretomanid.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Pretomanid.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO.</th>
                <th id="hd_h_Pretomanid.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Pretomanid.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Pretomanid.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pretomanid</td>
                <td headers="hd_h_Pretomanid.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/substance/135143585">187235-37-6</ext-link>
                </td>
                <td headers="hd_h_Pretomanid.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C14-H12-F3-N3-O5</td>
                <td headers="hd_h_Pretomanid.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135143585" document-id-type="sid" document-type="summary" object-id="135143585" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Pretomanid.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 04 November 2019</p>
        <ref-list id="Pretomanid.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Pretomanid.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Antituberculosis agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 611-21.<annotation><p><italic toggle="yes">(Extensive review of hepatotoxicity of antituberculosis medications published in 1999 before the availability of pretomanid).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pretomanid.REF.verma.2013">
            <mixed-citation publication-type="book">Verma S, Kaplowitz N. Hepatotoxicity of antituberculosis drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 483-504.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of antituberculosis drugs published before the availability of bedaquiline or pretomanid).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pretomanid.REF.gumba.2011">
            <mixed-citation publication-type="book">Gumba T. Chemotherapy of tuberculosis, mycobacterium avium complex disease and leprosy. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1549-70.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Pretomanid.REF4">
            <mixed-citation publication-type="web">
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000OtherR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000OtherR.pdf</ext-link>
              <annotation>
                <p>
                  <italic toggle="yes">(FDA website with review of safety and efficacy of pretomanid includes specific analysis of its potential hepatotoxicity [pages 31-49]).</italic>
                </p>
              </annotation>
            </mixed-citation>
          </ref>
          <ref id="Pretomanid.REF.ginsberg.2009.3720">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ginsberg</surname>
                  <given-names>AM</given-names>
                </name>
                <name name-style="western">
                  <surname>Laurenzi</surname>
                  <given-names>MW</given-names>
                </name>
                <name name-style="western">
                  <surname>Rouse</surname>
                  <given-names>DJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Whitney</surname>
                  <given-names>KD</given-names>
                </name>
                <name name-style="western">
                  <surname>Spigelman</surname>
                  <given-names>MK</given-names>
                </name>
              </person-group>
              <article-title>Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects.</article-title>
              <source>Antimicrob Agents Chemother</source>
              <year>2009</year>
              <volume>53</volume>
              <fpage>3720</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 58 healthy volunteers dose once daily with pretomanid [15 to 1500 mg] once daily for up to 7 days, there were &#x0201c;no significant or serious adverse events&#x0201d;; no mention of ALT or AST elevations).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19528280</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.diacon.2012.3027">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Diacon</surname>
                  <given-names>AH</given-names>
                </name>
                <name name-style="western">
                  <surname>Dawson</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>du Bois</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Narunsky</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Venter</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Donald</surname>
                  <given-names>PR</given-names>
                </name>
                <name name-style="western">
                  <surname>van Niekerk</surname>
                  <given-names>C</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Phase II dose-ranging trial of the early bactericidal activity of PA-824.</article-title>
              <source>Antimicrob Agents Chemother</source>
              <year>2012</year>
              <volume>56</volume>
              <fpage>3027</fpage>
              <lpage>31</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 69 South African adults with pulmonary tuberculosis enrolled in a dose-ranging 14-day study, response rates were similar with 100 and 200 mg daily and there were no drug related serious adverse events; no mention of ALT or AST elevations).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22430968</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Reuben</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>DG</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>WM</given-names>
                </name>
                <collab>Acute Liver Failure Study Group</collab>
              </person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were linked to pretomanid).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.diacon.2012.3271">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Diacon</surname>
                  <given-names>AH</given-names>
                </name>
                <name name-style="western">
                  <surname>Donald</surname>
                  <given-names>PR</given-names>
                </name>
                <name name-style="western">
                  <surname>Pym</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Grobusch</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Patientia</surname>
                  <given-names>RF</given-names>
                </name>
                <name name-style="western">
                  <surname>Mahanyele</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Bantubani</surname>
                  <given-names>N</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.</article-title>
              <source>Antimicrob Agents Chemother</source>
              <year>2012</year>
              <volume>56</volume>
              <fpage>3271</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(47 patients with multidrug resistant tuberculosis were treated with bedaquiline or placebo with background regimens for up to 6 months; major side effects not mentioned).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22391540</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.roehr.2012.e2216">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Roehr</surname>
                  <given-names>B.</given-names>
                </name>
              </person-group>
              <article-title>Trial tests new combination of drugs to treat tuberculosis.</article-title>
              <source>BMJ</source>
              <year>2012</year>
              <volume>344</volume>
              <elocation-id>e2216</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(News report that the Global Alliance for TB Drug Development had launched a trial of pretomanid [PA 824], a new drug candidate for drug resistant tuberculosis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22434129</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.centers_for_disease_control_and_prevention.2013.1">
            <element-citation publication-type="journal">
              <person-group>
                <collab>Centers for Disease Control and Prevention</collab>
              </person-group>
              <article-title>Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.</article-title>
              <source>MMWR Recomm Rep</source>
              <year>2013</year>
              <month>Oct</month>
              <day>25</day>
              <volume>62</volume>
              <issue>RR-09</issue>
              <fpage>1</fpage>
              <lpage>12</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Recommendations on use of bedaquiline mentions that patients should be monitored monthly and bedaquiline should be discontinued for persistent ALT or AST elevations, concurrent elevations of serum bilirubin, ALT or AST elevations above 8 times the ULN, or any liver test abnormalities accompanied by symptoms of liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24157696</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.dooley.2014.5245">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dooley</surname>
                  <given-names>KE</given-names>
                </name>
                <name name-style="western">
                  <surname>Luetkemeyer</surname>
                  <given-names>AF</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>JG</given-names>
                </name>
                <name name-style="western">
                  <surname>Allen</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Cramer</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Murray</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Sutherland</surname>
                  <given-names>D</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>AIDS Clinical Trials Group A5306 Study Team. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.</article-title>
              <source>Antimicrob Agents Chemother</source>
              <year>2014</year>
              <volume>58</volume>
              <fpage>5245</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Study of pharmacokinetics of pretomanid when combined with various antiretroviral agents demonstrated that maximal plasma levels were reduced when combined with efavirenz [-28%] or rifampin [-53%], but reductions were less [-13%] when combined with lopinavir-ritonavir).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24957823</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 408 were attributed to antimicrobial agents including 52 to antituberculosis agents, but no cases were attributed to pretomanid or bedaquiline).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.dawson.2015.1738">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dawson</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Diacon</surname>
                  <given-names>AH</given-names>
                </name>
                <name name-style="western">
                  <surname>Everitt</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>van Niekerk</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Donald</surname>
                  <given-names>PR</given-names>
                </name>
                <name name-style="western">
                  <surname>Burger</surname>
                  <given-names>DA</given-names>
                </name>
                <name name-style="western">
                  <surname>Schall</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.</article-title>
              <source>Lancet</source>
              <year>2015</year>
              <volume>385</volume>
              <issue>9979</issue>
              <fpage>1738</fpage>
              <lpage>47</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 207 adults with pulmonary tuberculosis treated with standard therapy or pretomanid in combination with moxifloxacin and pyrazinamide for 8 weeks, antimycobacterial activity was similar with all regimens and pretomanid regimens had excellent activity against multidrug resistant infections, while adverse event rates were similar including ALT or AST elevations above 3 times ULN [12%, 17% and 18% in the 3 pretomanid arms vs 12% in controls]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25795076</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.dheda.2019.820">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dheda</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Gumbo</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Maartens</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Dooley</surname>
                  <given-names>KE</given-names>
                </name>
                <name name-style="western">
                  <surname>Murray</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Furin</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Nardell</surname>
                  <given-names>EA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Lancet Respiratory Medicine drug-resistant tuberculosis Commission group. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.</article-title>
              <source>Lancet Respir Med</source>
              <year>2019</year>
              <volume>7</volume>
              <fpage>820</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the epidemiology, pathogenesis, diagnosis and management of multidrug resistant tuberculosis; does not discuss hepatotoxicity of therapeutic drug regimens).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31486393</pub-id>
            </element-citation>
          </ref>
          <ref id="Pretomanid.REF.keam.2019">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Keam</surname>
                  <given-names>SJ</given-names>
                </name>
              </person-group>
              <article-title>Pretomanid: First Approval.</article-title>
              <source>Drugs</source>
              <year>2019</year>
              <month>Oct</month>
              <day>3</day>
              <comment>[Epub ahead of print]</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Summary of the US FDA approval of pretomanid combined with bedaquiline and linezolid as therapy of multidrug resistant tuberculosis for 26 weeks; mentions that common adverse events noted in the 109 patients treated in registration trials included peripheral neuropathy [81%], acne [39%], anemia [37%], nausea [37%], vomiting [34%], myalgia [29%], headache [28%], increased aminotransferase [28%] and GGT levels [17%], dyspepsia [24%], anorexia [22%], rash [21%], pruritus [20%] and abdominal pain [19%], but there were no liver related serious adverse events or deaths).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31583606</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Pretomanid.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed?cmd=search&#x00026;pubmedfilters=true&#x00026;term=(Pretomanid%2FAE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice%2FCI+OR+bile+duct+diseases%2FCI+OR+liver%2FDE+OR+liver+diseases%2FCI)+AND+(%221900%2F1%2F1%22%5BEDat%5D%3A%222999%2F12%2F31%22%5BEDat%5D)">Recent References on Pretomanid: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Pretomanid">Trials on Pretomanid: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
